VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog
← Value Add PulseIPO$119.8B+ YTD

SpaceX's $60B Cursor Deal Puts the US on Track for a Record Startup M&A Year

Acquirers have spent at least $119.8 billion buying US startups so far in 2026, on pace to beat 2025's record, with SpaceX's $60 billion purchase of Cursor parent Anysphere -- the largest startup acquisition ever -- leading the charge. Biotech made up half the top-10 deals, signaling that the exit window has reopened broadly, not just for AI.

$119.8B+ (YTD)
2026 M&A Spend
SpaceX–Cursor $60B
Largest Deal
Google–Wiz $32B
Prior Record
$5.15B
Capital One–Brex
$4B
Qualcomm–Modular
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
June 25, 2026
2 min read
KEY TAKEAWAYS FOR VCs & FOUNDERS
1

A record M&A year is the liquidity relief venture has waited years for after a frozen exit market

2

The $60B Cursor deal nearly doubles the prior startup-acquisition record (Google-Wiz at $32B)

3

Biotech making up half the top deals shows the reopening extends well beyond AI

4

Newly public, cash-rich acquirers like SpaceX are using stock to go shopping at scale

TC
The VC Read · Trace's TakeTrace Cohen

After years of LPs begging for distributions, a record M&A year is the relief valve venture desperately needed -- and the most underappreciated part is that it's not just AI. Biotech being half the top-10 deals means the exit window reopened broadly, which is what real thaws look like. The deeper lesson sits in the Cursor deal: an IPO doesn't just mint liquidity, it mints acquirers, and newly public SpaceX is now spending stock the market prices by the second. Watch deal volume, not just the headline dollars -- one $60B outlier can flatter a tape that's thinner underneath.

📈 2026 IPO Tracker →💰 Funding Tracker →

Acquirers have spent at least $119.8 billion buying US startups so far in 2026, putting the year on pace to exceed 2025's record-setting tally, according to Crunchbase News. The catalyst-in-chief is SpaceX's $60 billion acquisition of Cursor and its parent Anysphere -- the largest startup purchase ever, nearly double the previous record, which SpaceX consummated after its IPO this month using an option it took out in April.

The context reframes the deal. Before Cursor, the biggest startup acquisition on record was Google's $32 billion purchase of cloud-security firm Wiz, followed by Facebook's $19 billion WhatsApp deal in 2014. Cursor at $60 billion doesn't just break the record -- it laps it, and it demonstrates how an IPO transforms a company into an acquirer: SpaceX is spending freshly liquid public stock, the same playbook that turned Google and Meta into serial dealmakers.

“Biotech accounted for half of 2026's top-10 deals, including Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion -- the largest biotech buyout in years.”

Crucially, the M&A surge isn't an AI-only story. Biotech accounted for half of 2026's top-10 deals, including Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion -- the largest biotech buyout in years. Other marquee transactions include Capital One acquiring fintech Brex for $5.15 billion and Qualcomm buying AI-chip startup Modular for $4 billion. The breadth signals that the exit market has thawed across sectors, not just for the AI darlings.

For venture, this is the liquidity story that matters. After years of a frozen exit environment that left LPs starved for distributions and funds unable to recycle capital, a record M&A year -- alongside a reopening IPO window featuring SpaceX, and OpenAI and Anthropic in the wings -- finally puts cash back into the ecosystem. Strategic acquirers paying public-comparable prices for category leaders is exactly the signal founders and GPs have been waiting for.

The bear case: a record dollar figure driven by a single $60 billion outlier can mask thinner activity beneath the headline, and M&A booms can cool fast if public markets wobble or antitrust posture shifts. What to watch: whether deal volume (not just value) sustains through the second half, how regulators treat the largest transactions, and whether the newly public AI winners keep using their stock to buy.

ShareXLinkedInEmail
More onSpaceX →Cursor →

Originally reported by Crunchbase News. Analysis and editorial commentary by Value Add Pulse.

← Back to Pulse

Markets Now

live
SPCX▲+0.73%
$233.10
CBRS▲+0.66%
$259.80
SPY▲+0.07%
5,952.40
QQQ▲+0.12%
20,061.30
NVDA▼-0.98%
$152.10
MSFT▲+0.29%
$482.60
GOOGL▲+0.34%
$209.10
META▲+0.23%
$655.40

Read Next

IPO

OpenAI and Anthropic File Confidential S-1s, Racing to Public Markets

OpenAI and Anthropic have both confidentially filed S-1s, with OpenAI targeting a Q4 2026 listing as Anthropic -- fresh off a ~$65B round lifting its valuation toward $965B -- races it to public markets. When both labs trade, every MANGOS member will be in public hands.

IPOS-1 filed

Jupiter Neurosciences Files an S-1 as It Pushes JOTROL Into Parkinson's Trials

Clinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register additional capital as it advances JOTROL, its enhanced resveratrol formulation, into a Phase 2a Parkinson's disease trial. The filing adds a CNS-focused name to a 2026 capital-markets pipeline that biotech is increasingly populating alongside AI and chips.

IPOIPO imminent

Low-Power Chipmaker Ambiq Micro Files S-1MEF, Racing Toward an Imminent IPO Pricing

Ambiq Micro, the ultra-low-power semiconductor company whose chips power wearables and edge-AI devices, filed an S-1MEF with the SEC -- a registration that companies submit immediately before an IPO prices. The filing signals Ambiq is in the final stretch toward going public as appetite for chip and edge-AI names returns.

@Trace_Cohen·t@nyvp.com